Call for Papers  

Article Details

Review Article

The Role and Therapeutic Potential of Non-coding RNAs in Resistance to EGFR-TKIs targeted therapy for Non-small Cell Lung Cancer


Yang Zhang, Ye Chen, Li-Li Lu, Xiu-Li Xie, Ren Huan, Li-Fang Wu, Li-Na Tan, Tao Xu and Yong Jin*   Pages 1 - 25 ( 25 )


Lung cancer is the leading cause of cancer-related deaths worldwide, of which non-small cell lung cancer (NSCLC) is the most common type, and epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are widely used for the treatment of NSCLC. EGFR-TKIs are known to develop a drug-resistant response after a certain number of cycles of dosing, and how to alleviate or even reverse EGFR-TKI resistance is an urgent problem at present. This review focuses on the role of ncRNAs in the resistance of NSCLC to EGFR-TKIs and the potential mechanisms underlying the development of NSCLC resistance to EGFR-TKIs. NcRNAs are involved in NSCLC resistance to EGFR-TKIs by mediating cellular drug efflux, epithelial-mesenchymal transition, apoptosis, autophagy, and EGFR mutation. ncRNAs play a crucial role in NSCLC resistance to EGFR-TKIs. Hopefully, the results will provide some guidance and help for the treatment and prognosis of NSCLC.


Non-coding ribonucleic acid (ncRNA), non-small cell lung cancer (NSCLC), drug resistance mechanisms, EGFR-TKIs, chemoresistance, ncRNA-based therapy.


Read Full-Text article